Project description
AI advances Parkinson’s disease diagnosis
Parkinson's disease (PD) is characterised by the progressive loss of dopamine-producing brain cells, leading to diverse motor and non-motor symptoms. PD is often missed or misdiagnosed as early signs are subtle and common with other diseases, while selecting the optimal treatment is usually a lengthy process, leading to unnecessary suffering. Funded by the Horizon Europe programme, the AI-PROGNOSIS project aims to advance PD diagnosis and care by harnessing the power of AI. The consortium will develop predictive models for PD risk and prognosis based on in-depth health and genetic data and combine them with specific biomarkers measured in everyday life. Project work will lead to the creation of a digital health toolkit offering persons affected by PD and healthcare professionals valuable insights for informed health management.
Objective
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, with a multifactorial aetiology, heterogeneous manifestation of motor and non-motor symptoms, and no cure. PD is often missed or misdiagnosed, as early symptoms are subtle and common with other diseases, allowing for considerable damage to occur before treatment. Moreover, selecting the optimal medication regimen is usually a lengthy, “trial and error” process, leading to critical, costly non-adherence. Following a trustworthy and inclusive approach to AI development and based on multidisciplinary expertise and broad stakeholder engagement, AI-PROGNOSIS aims to advance PD diagnosis and care by: 1) developing novel, predictive AI models for personalised PD risk assessment and prognosis (in terms of time to higher disability transition and response to medication) based on multi-source patient records and databases, including in-depth health, phenotypic and genetic data, 2) implementing a system of biomarkers informing the AI models by tracking key risk/progression markers in daily living, and ultimately 3) translating the models and digital biomarkers into a validated, privacy-aware AI-driven toolkit, supporting healthcare professionals (HCPs) in disease screening, monitoring and treatment optimization via quantitative, explainable evidence, and empowering individuals with/without PD with tailored insights for informed health management.
Fields of science
Keywords
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
546 36 THESSALONIKI
Greece
See on map
Participants (15)
3001 Leuven
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1253 Luxembourg
See on map
15232 ATHINA
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
751 05 Uppsala
See on map
65205 Wiesbaden
See on map
31052 Toulouse Cedex 3
See on map
1495-688 Cruz Quebrada Lisboa
See on map
57001 Thermi Thessaloniki
See on map
86633 Neuburg An Der Donau
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
3000 Leuven
See on map
1000 Bruxelles / Brussel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
01069 Dresden
See on map
1006 Riga
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2371 AGIOS DOMETIOS
See on map
28002 Madrid
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (2)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
WC2R 2LS London
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
OX1 2JD Oxford
See on map